Yago Garitaonaindia, Translational Research Fellow at CCIT-DK – National Center for Cancer Immune Therapy of Denmark, shared a post on X:
“New in EJC: among PD-(L)1 responders, durability tracks response depth, not tumor type
Our nationwide cohort : 2,127 responders (melanoma, RCC, NSCLC)
- Within CR and within PR, PFS near-identical across tumors
- PR vs CR = dominant factor
Two papers, two faces of the same coin : response depth, not tumor type, drives the risk of acquired resistance to IO
Trial-level (JNCCN) + real-world (EJC), same conclusion
Cheers to Marco Donia and CCITdk.”
Title: Progression risk among responders to PD-1/PD-L1 blockade is primarily stratified by response depth: a nationwide cohort study of 2,127 patients with melanoma, RCC, and NSCLC
Authors: Rikke Andersen, Mette Syberg Jespersen, Mario Presti, Birgitte Bjornhart, Anne-Cathrine Østby, Anne Kirstine Moeller Darras, Yago Garitaonaindia, Christina Halgaard Ruhlmann, Malene Støchkel Frank, Henrik Schmidt, Rasmus Blechingberg Friis, Louise Mahncke Guldbrandt, Jon Røikjær Henriksen, Andreas Bjerrum, Kira Schreiner Simonsen, Jesper Andreas Palshof, Troels Holz Borch, Jon Lykkegaard Andersen, Soeren Kjaer, Niels Viggo Jensen, Aziza Azimi, Ane Bundsbaek Iversen, Peter Meldgaard, Sara Grønbech Steen, Shawez Khan, Adam Andrzej Luczak, Stine Wahlstrøm, Daniela Zitnjak, Inge Marie Svane, Niels Fristrup, Charlotte Kristiansen, Gitte Fredberg Persson, Lars Bastholt, Mette Poehl, Eva Ellebaek, and Marco Donia.
Read the full article on EJC.
Other articles featuring Yago Garitaonaindia on OncoDaily.
